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Abstract
Introduction: Bone marrow lesion (BML) size may be an important imaging biomarker for osteoarthritis-related
clinical trials and reducing BML size may be an important therapeutic goal. However, data on the interrelationships
between BML size, pain, and structural progression are inconsistent and rarely examined in the same cohort.
Therefore, we evaluated the cross-sectional and longitudinal associations of BML volume with knee pain and joint
space narrowing (JSN).
Methods: A BML volume assessment was performed on magnetic resonance images of the knee collected at the
24- and 48-month Osteoarthritis Initiative visits from a convenience sample of 404 participants in the progression
cohort. During the same visits, knee pain was assessed with WOMAC pain scores and knee radiographs were
acquired and scored for JSN. BML volume was summed to generate a total knee volume and an index tibiofemoral
compartment volume (compartment with greater baseline JSN). Primary analyses included multiple linear
regressions (outcome = pain, predictor = total knee BML volume) and logistic regressions (outcome = JSN,
predictor = index tibiofemoral compartment BML volume).
Results: This sample was 49% female with a mean age of 63 (9.2 standard deviation (SD)) years, and 71% had
radiographic osteoarthritis in the study knee. Larger baseline BMLs were associated with greater baseline knee pain
(P = 0.01), the presence of JSN at baseline (odds ratio (OR) = 1.50, 95% confidence interval (CI) = 1.23 to 1.83), and
JSN progression (OR = 1.27, 95%CI = 1.11 to 1.46). Changes in total knee BML volume had a positive association
with changes in knee pain severity (P = 0.004) and this association may be driven by knees that were progressing
from no or small baseline BMLs to larger BMLs. In contrast, we found no linear positive relationship between BML
volume change and JSN progression. Instead, regression of medial tibiofemoral BML volume was associated with
JSN progression compared to knees with no or minimal changes in BML volume (OR = 3.36, 95%CI = 1.55 to 7.28).
However, follow-up analyses indicated that the association between JSN progression and BML volume change may
primarily be influenced by baseline BML volume.
Conclusion: Large baseline BMLs are associated with greater baseline knee pain, the presence of JSN at baseline,
and disease progression. Additionally, BML regression is associated with decreased knee pain but not a reduced
risk of concurrent JSN progression.
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Introduction
Knee osteoarthritis (OA) is commonly characterized by
periarticular bone changes [1-6]. For example, bone
marrow lesions (BMLs; see Figure 1) are related to OA
severity and may predict OA progression [1-8]. Further-
more, incident or enlarging BMLs are associated with
incident and increased knee pain [9-11] especially
among knees without OA or when the baseline BML
size is small and the increase in size is large [9-11]. In
addition to changes in knee pain, several studies using
semi-quantitative outcomes or two-dimensional mea-
surements suggest that an increase in BML size is asso-
ciated with cartilage loss; however, the temporal order
of these pathologic changes remains unclear [5,12-14].
Based on these associations, BML size may be an
important imaging biomarker for clinical trials [15] and
reducing BML size may be an important therapeutic goal
for disease modification [16,17]. For BMLs to function in
this role, changes in their size should reflect changes in
disease activity, however, data on the inter-relationships
between BML size, pain, and structural progression are
inconsistent [9,10,12,14] and rarely examined in the same
cohort. It may be beneficial to explore the longitudinal
association between BML size and structural progression
as well as knee pain in the same cohort.
Therefore, the purposes of these analyses were to eval-
uate the cross-sectional and longitudinal associations
between BML volume and knee pain as well as joint
space narrowing (JSN), with an emphasis on exploring
decreases in BML size. We hypothesized that larger
baseline BML sizes will be associated with greater base-
line knee pain and the presence of JSN as well as greater
increases in knee pain and JSN progression over
24 months. Furthermore, we hypothesized that changes
in BML size would have a positive linear association
with changes in knee pain and JSN progression. There-
fore, we anticipated that decreases in BML size would
be associated with decreases in knee pain and reduced
odds of JSN progression. The results of these analyses
may provide further evidence to support or refute the
utility of BML reduction as a therapeutic goal and BML
volume as an imaging biomarker for clinical trials.
Methods
To assess the associations between BML volume and
knee pain as well as JSN we used images and data
obtained from the Osteoarthritis Initiative (OAI). The
OAI is a multicenter observational cohort study of knee
OA that collected longitudinal clinical and image data
[18] as well as biospecimens from 4,796 participants
over an eight-year follow-up period. The primary vari-
ables (knee pain, JSN, and BML volume) were from the
24-month and 48-month OAI visits. OAI data are avail-
able for public access [19].
Participant selection
The OAI participants were classified at baseline into
three subcohorts, which included the progression (n =
1,389) subcohort that was characterized by participants
with symptomatic radiographic knee OA in at least one
knee. Symptomatic radiographic knee OA was defined
as a knee with a definite osteophyte (Osteoarthritis
Research Society International (OARSI) Atlas [20] osteo-
phyte grade 1 to 3) and symptoms (’pain, aching or stiff-
ness on most days of the month in the last year’).
The Bone Ancillary Study recruited participants (n =
629) in the OAI progression subcohort during their 30-
or 36-month OAI visits. An inclusion criterion for this
ancillary study was a willingness to undergo additional
knee imaging. Exclusion criteria were contraindication
for magnetic resonance (MR) imaging and the presence
of bilateral knee replacements. For these analyses, we
focused on participants in the Bone Ancillary Study
with MR imaging at the 24- and 48-month OAI visits
(n = 478). We then excluded knees that had imaging
artifact (for example, motion) or the bone segmentation
program failed to delineate the bone borders (n = 442).
From this sample, we selected the first 404 knees as a
convenience sample. MR images from these visits were
selected because of the time period overlaps with the
data collected for the Bone Ancillary Study. This study
Figure 1 Bone marrow lesion (BML) in the medial tibia. The red
lines identify the bone boundary and the yellow lines surround
areas of high signal intensity. The three small regions (two in femur,
one in tibia) would be excluded from analyses since they do not
appear on more than one image.
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received ethical approval from each OAI clinical site
(Memorial Hospital of Rhode Island Institutional Review
Board, Ohio State University’s Biomedical Sciences Insti-
tutional Review Board, University of Pittsburgh Institu-
tional Review Board, and University of Maryland
Baltimore - Institutional Review Board), the OAI coordi-
nating center (Committee on Human Research at
University of California, San Francisco), as well as the
Institutional Review Board at Tufts Medical Center and
Tufts University Health Sciences Campus. All partici-
pants provided informed consent to the OAI and the
Bone Ancillary Study.
Magnetic resonance imaging
All BML measurements were performed using sagittal
intermediate-weighted, turbo spin echo, fat-suppressed
MR sequences (field of view = 160 mm, slice thickness =
3 mm, skip = 0 mm, flip angle = 180 degrees, echo time =
30 ms, recovery time = 3200 ms, 313 × 448 matrix (inter-
polated to 512 × 512), phase encode superior/inferior, ×
resolution = 0.357 mm, and y resolution = 0.511 mm)
[18]. The measured images were acquired at the 24- and
48-month OAI visits with one of four identical Siemens
(Erlangen, Germany) Trio 3-Tesla MR systems and a USA
Instruments (Aurora, OH, USA) quadrature transmit-
receive knee coil at the four OAI clinical sites.
For these analyses, we focused on the primary OAI
knee, which was the right knee unless there was a con-
traindication for MR imaging (for example, the presence
of metal), in which case, the left knee was the primary
OAI knee. This knee was selected because, according to
the OAI protocol, it underwent a complete set of OAI
MR sequences, while the contralateral knee had an
abbreviated MR scan to reduce participant burden.
Therefore, the primary OAI knee was not always the
knee with symptomatic OA.
Semi-automated BML segmentation
Two readers measured BML volume with a semi-
automated segmentation method that detects, extracts,
and quantifies the structure of BMLs based on the sagit-
tal intermediate weighted, turbo spin echo, fat-sup-
pressed MR sequence. We have previously reported the
construct validity of this method with OAI images by
demonstrating that increases in BML volume were asso-
ciated with cartilage loss and BML volumes differed
across the Boston Leeds Osteoarthritis Knee Score [21].
This semi-automated segmentation method has been
described in more detail elsewhere [21]; but briefly, the
only manual step required a reader to use a custom gra-
phical user interface (MATLAB, MathWorks, Inc., Natick,
MA, USA) to manually identify the crude boundaries of
the tibia and femur in each slice of the MR imaging data
set by marking multiple points along the articular surface.
For the border furthest from the articular surface, the
reader marked the bone just prior to the epiphyseal line or
at the edge of bone and soft tissue. In addition, we omitted
the central slices from the analyses (that is, the middle
nine slices; 2.7 cm) to focus on BMLs adjacent to the
chondral surface and to improve reliability. The program
automatically refined the initial estimate to more precisely
identify the bone boundaries (see red lines in Figure 1).
Next, the program automatically performed a thresholding
and curve evolution process twice to segment the areas of
high signal intensity, which may represent a probable
BML (see yellow lines in Figure 1). We then used two cri-
teria to eliminate the false-positive regions and to opera-
tionally define a BML: (1) the distance between a BML to
the articular surface should be no more than 10 mm
[6,22,23] and (2) a BML should span more than one MR
image. BML volumes were calculated for four discrete
regions: medial femur, lateral femur, medial tibia, and
lateral tibia.
Intra-reader and inter-reader reliability were assessed for
the two readers and the details of those methods have
been previously described [21]. Intra-reader reliability for
BML change was good to excellent for reader one (intra-
class correlation coefficient (ICC) (3,1 model) = 0.79 to
>0.99, n = 10) and reader two (ICC (3,1 model) = 0.95 to
0.96, n = 12). Inter-reader reliability for BML volume
change was good for the lateral femur and tibia as well as
the medial femur (ICC (2,1 model) = 0.83 to 0.93) but low
for the medial tibia BML volume change (ICC (2,1 model)
= 0.59). To ensure consistency between readers a third
investigator reviewed all of the BML segmentations. The
third investigator was responsible for ensuring that the
bone segmentation was consistent across time and knees.
The same reader always measured the baseline and follow-
up images to avoid inter-reader error in the BML change
measurements.
Knee pain
Knee pain was assessed in the primary OAI knee with a
knee-specific WOMAC (Western Ontario and McMaster
Universities) pain score. The WOMAC pain score was
derived from five 5-point Likert-based questions that
inquire about knee pain over the last seven days when
performing different activities (walking, stairs, in bed,
seated or lying down, and standing). The WOMAC pain
score is a well-validated pain assessment that is com-
monly used for pain related to knee OA [24]. WOMAC
pain scores at the 24- and 48-month OAI visits are pub-
licly available (Files: AllClinical03_SAS (version 3.4) and
AllClinical06_SAS (version 6.2)) [19].
Knee radiographs
Weight-bearing, bilateral, fixed-flexion, posterior-anterior
knee radiographs were obtained at the 24- and 48-month
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OAI visits. Central readers, who were blinded to
sequence, scored the paired images for medial and lateral
JSN grade (0 to 3) using the OARSI Atlas [20] as well as
within OARSI grade narrowing [25]. The agreement for
these readings (read-reread) was good (weighted kappa
(intra-rater reliability) = 0.75 to 0.88). These JSN scores
are publicly available (Files: kXR_SQ_BU03_SAS(version
3.4) and kXR_SQ_BU06_SAS (version 6.20) [19].
Confirmatory analyses
To verify the primary results for structural (JSN) progres-
sion we used data from a clinical trial of vitamin D among
patients with knee OA (n = 103) [6,26]. The advantage of
this data set was that we had manually measured BMLs,
which allowed us to verify our findings using a different
BML measurement method and a different structural out-
come measure - cartilage thickness [6]. The methods to
measure BMLs and cartilage thickness have been reported
previously [6,26]. Briefly, femoral and tibial cartilage was
manually segmented by one reader in the index tibiofe-
moral compartment (compartment with greater JSN; ICC
>0.99). Furthermore, one reader measured the longest
cross-sectional diameter of each BML in three planes to
approximate BML volume (ICC = 0.90). Approximate
BML volumes were then summed to form a compart-
ment-specific BML volume.
Statistical analyses
Demographic and anthropometric descriptive statistics
were calculated for the samples used in each analysis (data
is publicly available [19]). We used chi-square tests and
independent-sample t tests to determine if these partici-
pant characteristics were different between our OAI study
sample and the remainder of the progression subcohort
that was not included in our primary analyses. Further-
more, we calculated the descriptive characteristics of base-
line BML volume and BML volume change (follow-up
volume minus baseline volume).
Among the full cohort, we explored the distribution of
total BML volume change (total BML volume = medial
femur + lateral femur + medial tibia + lateral tibia) when
stratified by tertiles based on baseline total BML volume
(no or small BML volume, moderate BML volume, large
BML volume). Total BML volume change was stratified
into quartiles but the middle two quartiles were col-
lapsed. Therefore, the lowest quartile represented knees
with BML regression, the middle two quartiles repre-
sented knees with no or minimal changes in BML
volumes, and the highest quartile represented knees with
BML progression (enlargement).
Total bone marrow lesion volumes and knee pain
Three multiple linear regression models were used to
evaluate the association between WOMAC pain
(continuous variable), as an outcome, and total BML
volume (continuous variable) while controlling for sex,
weight (at 24-month visit), height (at 24-month visit),
and age (at 24-month visit). The first model was used to
assess the association between baseline WOMAC pain
(continuous variable) and baseline total BML volume
(continuous variable). The second and third models
explored the associations between WOMAC pain
change (continuous variable) and baseline total BML
volume and total BML volume change (continuous vari-
ables), respectively. Prior to the analyses we verified a
linear relationship between WOMAC pain (baseline and
change) and total BML volume (baseline and change).
To further explore the associations between WOMAC
pain change and total BML volume change we assessed
the associations stratified among tertiles based on base-
line BML volume. Based on diagnostic tests (for exam-
ple, DFFITS, Cook’s D) that yielded poor diagnostics for
the linear regression models within tertiles, we opted to
perform robust regression models.
Unicompartmental bone marrow lesion volumes and joint
space narrowing
Three logistic regression models were used to evaluate
the association between JSN, as an outcome, and BML
volume in the index tibiofemoral compartment. The first
model was used to assess the association between the
presence of JSN at baseline (dichotomous variable) and
baseline BML volume (continuous variable). The second
and third models explored the associations between JSN
progression (dichotomous variable) and baseline BML
volume (continuous variable) and BML volume change
(three classifications), respectively. The JSN analyses
were limited to the index tibiofemoral compartment,
which was defined as the compartment with greater JSN
at baseline. JSN progression was defined as any increase
in OARSI JSN scores, including within grade changes
[25]. For models with JSN progression as the outcome we
excluded knees with severe JSN (OARSI JSN score = 3)
since these knees could not progress. The BML volume
was the sum of the femur and tibia BML volumes in the
index compartment. In the logistic regressions, we con-
trolled for sex, body mass index (at 24-month visit), and
age (at 24-month visit). We adjusted for body mass index
instead of weight and height because of the limited num-
ber of knees with JSN progression.
We evaluated the point estimates across quartiles of
each continuous independent variable (that is, age, body
mass index, baseline BML volume, and BML volume
change) to verify if they had a linear relationship with
the outcomes. Age did not have a linear relationship
with the outcomes; therefore, we converted age to a bin-
ary variable (<65 years, ≥65 years). Body mass index also
did not have a linear relationship with the outcomes
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and was converted to a binary variable (<30 kg/m2,
≥30 kg/m2). Finally, BML volume change did not have a
linear relationship with the presence of JSN progression.
Therefore, we analyzed the association between JSN
progression and BML volume change quartiles with the
middle two quartiles collapsed. Therefore, the lowest
quartile represented knees with BML regression, the
middle two quartiles represented knees with no or mini-
mal changes in BML volumes (reference group), and the
highest quartile represented knees with BML progres-
sion (enlargement). Sensitivity analyses were performed
among knees with primarily medial tibiofemoral JSN.
Based on the results of the analyses noted above, we
used classification and regression trees (CART) [27,28] to
determine whether baseline BML volume or BML volume
change was more influential in predicting JSN progression
over 24 months. JSN progression was used as the outcome
in CART analysis and the predictors were baseline BML
volume, BML volume change, age, sex, and body mass
index. One advantage of CART is that for a given set of
predictors, CART searches for the optimal cut point that
best discriminates between participants with and without
JSN progression. Statistical significance was defined as P ≤
0.05. All analyses were performed in SAS 9.3 (SAS Insti-
tute Inc., Cary, NC, USA) with the exception of the CART
analyses, which were conducted in R 2.15.0 using the rpart
function.
Confirmatory follow-up analyses
To verify the primary structural findings, we performed a
logistic regression model to examine the association
between manually measured BML size change (classified
as BML regression (change <-3.2 cm3), no change (change
± 3.2 cm3), or BML progression (change >3.2 cm3) [6])
and the outcome of tibial cartilage thickness derived from
manual cartilage segmentation (stratified into tertiles). The
model for femoral cartilage thickness was omitted from
the results because it did not meet the assumptions of lin-
earity (score test for the proportional odds assumption;
P = 0.02).
Results
The descriptive characteristics of the cohort (n = 404)
and the remainder of the progression subcohort that
was not included in these analyses, are reported in
Table 1. The average baseline total knee BML volume
ranged from 0.1 to 15.5 cm3 and the total knee BML
volume change ranged from -12.7 to 10.2 cm3 (see
Figure 2). The distribution of BML volume change stra-
tified by baseline BML volume is described in Table 2.
Most knees with no to moderate baseline total BML
volume showed minimal or no BML change. In contrast,
the majority of knees with large baseline total BML
volume experienced BML regression over 24 months.
Total bone marrow lesion volumes and knee pain
The associations between WOMAC pain and total BML
volume are described in Table 3 (n = 404). Larger total
baseline BML volumes were associated with greater
knee pain. Furthermore, BML volume change was posi-
tively associated with change in knee pain (for example,
an increase in BML volume was associated with
increased knee pain).
Since prior research suggested the association between
BML change and pain may be more pronounced among
knees progressing from no or small BMLs at baseline,
we further explored the association between WOMAC
pain change and BML volume change by conducting
stratified analyses by baseline BML volume (tertiles).
The robust regression models indicated that total BML
volume change and WOMAC pain change were signifi-
cantly related (estimate = 0.65, standard error = 0.25,
P = 0.009) only in the first tertile (no BMLs or BMLs
<1.0 cm3).
Unicompartmental bone marrow lesion volumes and joint
space narrowing
Among 375 knees with BML and JSN data, 246 (66%)
had JSN at baseline. This sample included 25 knees with
severe JSN (grade 3) that were excluded from analyses
of JSN progression. Among the remaining 350 knees,
68 (19%) knees had JSN progression over 24 months.
Larger baseline BML volume was associated with the
presence of baseline JSN in the same tibiofemoral com-
partment (odds ratio (OR) = 1.50 (95% confidence interval
(CI) = 1.23 to 1.82), c-statistic = 0.69). Knees without base-
line JSN had a median baseline BML volume of 0.49 cm3
(range 0.06 to 5.76 cm3). Knees with baseline JSN had a
median baseline BML volume of 1.13 cm3 (range 0.06 to
14.95 cm3).
Larger baseline BML volume was associated with JSN
progression in the same tibiofemoral compartment (odds
ratio = 1.28 (95% CI = 1.12 to 1.47), c-statistic = 0.70).
Knees without JSN progression had a median baseline
BML volume of 0.61 cm3 (range 0.06 to 14.57 cm3).
Knees with JSN progression had a median baseline BML
volume of 1.32 cm3 (range 0.08 to 14.95 cm3).
Table 4 shows the association between BML volume
change and JSN progression. Overall, BML volume
change was not significantly associated with JSN pro-
gression (P = 0.11). However, there was a trend that
BML regression and BML progression may be associated
with increased odds of JSN progression relative to knees
with no or minimal changes in BML volume.
Sensitivity analyses were performed among knees with
more severe medial tibiofemoral JSN than lateral tibiofe-
moral JSN. Among 317 knees, 188 (59%) had JSN at base-
line. This sample included 16 knees with severe JSN
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Females 199 (49%) 594 (60%)*
Age (years) 62.9 (9.2) 63.7 (9.0)
Weight (kg) 85.0 (15.4) 85.9 (16.4)
Height (m) 1.7 (0.1) 1.7 (0.1)
Right knee 390 (97%) n/a2
Kellgren and Lawrence grade ≥2 287 (71%) 539 (78%)*
Primarily lateral tibiofemoral OA 62 (15%) 110 (16%)
Baseline WOMAC pain score 3.3 (3.4) 4.1 (3.9)*
Baseline WOMAC pain score = 0 109 (27%) 189 (24%)
Change in WOMAC pain score 0.0 (3.0) -0.3 (3.4)
Change in WOMAC pain score = 0 102 (25%) 174 (24%)
Total knee BML volume (baseline; cm3) 2.6 (2.7) n/a
Total knee BML volume (change; cm3) -0.2 (2.1) n/a
Note: 1. Numbers for the remainder of the progression subcohort may vary due to missing data. 2. For the remainder of the progression subcohort we analyzed
the right knee for knee-specific outcomes. *P <0.05 for chi-square or independent-sample t tests comparing study sample to the remainders of the progression
subcohort. BML, bone marrow lesion; n/a, not applicable; OA, osteoarthritis; SD, standard deviation.
Figure 2 Scatter plot of WOMAC pain change by bone marrow lesion (BML) volume change stratified by tertiles (colors). Tertiles, based
on baseline BML volume, had average baseline total knee BML volumes of 0.6 ± 0.2 cm3, 1.6 ± 0.5 cm3, and 5.5 ± 2.9 cm3, respectively.
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(grade 3) that were excluded from analyses of JSN progres-
sion. Among the remaining 301 knees, 49 (16%) knees had
JSN progression over 24 months. Overall, we found that
medial tibiofemoral BML volume change was associated
with medial JSN progression (P = 0.01). Specifically, BML
regression in the medial tibiofemoral compartment was
statistically associated with increased odds of medial tibio-
femoral JSN progression (Table 4).
Based on the results above, we tried to determine
whether baseline BML volume or BML volume change was
more influential in modeling JSN progression over
24 months. In CART analyses the first split was based on
baseline BML volume, suggesting that this is the variable
best able to discriminate between those who did and did
not have JSN progression (see Figure S1 in Additional
file 1). The analysis classified participants with baseline
BML volume less than 0.95 cm3 as non-progressors
(including 22 who had JSN progression). For participants
with baseline BML volume greater than 0.95 cm3, classifi-
cation into the progressor and non-progressor groups
depended on further splits based on change in BML
volume, baseline BML volume, and age, resulting in 17 par-
ticipants correctly classified as progressors, 5 incorrectly
classified as progressors, and 29 incorrectly classified as not
progressing.
Confirmatory analyses: approximate BML volume and
cartilage change
In the confirmatory data set, 21 knees experienced BML
regression in the index tibiofemoral compartment,
49 knees experienced no change (reference group), and
33 had BML progression. While BML change was not
associated with tibial cartilage thickness (in tertiles, P =
0.08) there was a trend indicating BML regression
(OR = 2.72, 95% CI = 1.03 to 7.12) and BML progres-
sion (OR = 2.06, 95% CI = 0.88 to 4.57) were associated
with greater odds of cartilage thickness loss.
Discussion
Bone marrow lesion volume may have some utility as an
imaging biomarker for assessing knee OA severity and
predicting knee OA progression. However, reduction in
BML volume, which is associated with decreases in knee
pain, does not appear to indicate improvement in other
aspects of OA. Therefore, the use of BML volume as a
surrogate endpoint is not supported by this study.
Despite a lack of support for BML volume as a surro-
gate endpoint, this study demonstrates why assessing
BML volume at baseline may be beneficial. Based on
these analyses, we hypothesize that baseline BML size
may be more important than BML change when examin-
ing the association between BMLs and JSN progression.
These longitudinal findings may indicate that once a
knee experiences a large BML the joint has been structu-
rally compromised, at least for the next 24 months. BML
regression may represent changes that lead to decreased
knee pain (for example, reduced edema or fibrovascular
tissue) but may not reflect recovery of the bone structural
integrity (for example, periarticular bone mineral density,
trabecular morphometry), which may take longer to
remodel.
Consistent with what we found, cross-sectional [1,29-31]
and longitudinal analyses [2,6,8,11] have highlighted that
larger baseline BML size is associated with greater baseline
knee pain and structural damage as well as disease pro-
gression [2,4-8,13,14]. Baseline BML size may be particu-
larly important when assessing the associations between
changes in BML size and disease progression. For exam-
ple, our results provide additional evidence that the asso-
ciation between changes in knee pain and BML volume
may be more pronounced among knees with no or small
Table 2 Distribution of total BML volume change when stratified by tertiles based on total baseline BML volume
Total BML volume change (by quartile with middle two quartiles collapsed)




(Range: -12.7 to -0.8 cm3)
n (% of baseline tertile)
‘Minimal or
no BML change’
(Range: -0.8 to 0.4 cm3)
n (% of baseline tertile)
‘BML progression’
(Range: 0.4 to 10.2 cm3)
n (% of baseline tertile)
’No or Small BML volume’
(Range: 0.1 to 1.0 cm3)
0.0 (-0.7, 4.2) 0 (0.0%) 108 (80.6%) 26 (19.4%)
’Moderate BML volume’
(Range: 1.0 to 2.7 cm3)
-0.1 (-2.5, 5.0) 24 (17.8%) 68 (50.4%) 43 (31.9%)
’Large BML volume’
(Range: 2.7 to 15.5 cm3)
-1.1 (-12.7, 10.2) 77 (57.0%) 26 (19.3%) 32 (23.7%)
The division of total baseline bone marrow lesion (BML) volume and total BML volume change was based on tertiles. n = 404.
Table 3 Cross-sectional and longitudinal association
between BML volume and WOMAC pain volume
B (SE)* (P value)
Outcome: WOMAC Pain (baseline)
BML volume (baseline) 0.16 (0.06) 0.014
Outcome: WOMAC pain (change)
BML volume (baseline) -0.01 (0.06) 0.874
BML volume (change) 0.21 (0.07) 0.004
*All models adjusted for sex, weight, height, and age. n = 404. BML, bone
marrow lesion; B, parameter estimate; SE, standard error.
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baseline BMLs [11]. Additionally, we found that in the
association between JSN progression and BMLs it may be
that baseline BML size is more important than BML
volume change. These findings may be related to the
underlying structural changes associated with BMLs.
BMLs are characterized by altered subchondral bone
structure (for example, decreased mineral content, fibrosis,
edema, and altered trabecular morphometry) [32-38]. Per-
haps progression from no or small baseline BML coincides
with these changes leading to an increase in symptoms
and JSN progression. Therefore, large BMLs are associated
with abnormal bone structures. Once the bone has been
compromised with a large BML, a reduction in BML size
may reflect changes in the bone that can adapt quickly
and may be related to knee symptoms (for example, fibro-
sis, edema) but not reflect changes in structural integrity
(for example, mineral content, altered trabecular morpho-
metry), which may relate to risk of JSN progression and
take longer to recover.
This hypothesis is contingent on our findings that BML
regression, which is typical of larger baseline BMLs, was
associated with JSN progression. To verify these results,
we analyzed a different data set using manual measure-
ments of approximate BML volume and cartilage changes.
The confirmatory analyses, while not significant, indicated
similar trends as reported in the primary analyses. Further-
more, these results may be in agreement with prior work
from the MOST Study which reported that 28.1 to 29.3%
of regions with decreased BMLs had increases in cartilage
defect scores compared to 27.2% of those with stable
BMLs or 6.0% of those with no BMLs at baseline or fol-
low-up (these latter two groups represent a similar defini-
tion as our reference group with no to minimal changes)
[14]. Based on the results from the MOST Study [14] and
the current analyses, BML regression may not be an opti-
mal surrogate endpoint. To verify that BML regression
may not be an optimal surrogate endpoint, we replicated
the analyses with JSN progression using percent change in
BML volume to determine if percent change performed
differently in the statistical models than absolute change
but these analyses were not statistically significant (data
not shown). Based on the CART analysis, the analyses
with percent BML change may have been null because
smaller baseline BMLs (<0.95 cm3) would have consider-
able percent change even though the absolute change was
minimal (-0.8 to 0.4 cm3). This further supports the
hypothesis that BML regression (absolute change or per-
cent change) may not be an optimal surrogate endpoint.
Therefore, if we want to reduce the risk of cartilage loss or
JSN then BML prevention may be a more appropriate goal
than BML regression
While the study highlights the importance of baseline
BML size, it raises questions about interpreting BML
volume change that the current study could not address.
First, the semi-automated approach may include mea-
surement error associated with incorrectly identifying
areas of high signal intensity in the bone as BMLs. To
reduce the risk of incorrectly identifying areas of high
signal intensity as BMLs we established rules a priori
(that is, BMLs must be on consecutive images, BMLs
must be within 10 mm of articular cartilage, the central
nine slices were omitted). These rules systematically
exclude some BMLs, particularly in the central region of
the knee. For the pain analyses, the exclusion of centrally
located BMLs would likely lead to underestimates of the
strength of the association between BMLs and pain.
However, for the structural analyses, it is unlikely that
omitting the central slices would influence our results.
Hernandez-Molina et al. [39] reported that central BMLs
were not associated with cartilage loss unless they
extended into subchondral region in the index compart-
ment, which would have been detected with our segmen-
tation method. Future research with semi-quantitative
readings may help us better understand the implications
Table 4 Association between joint space narrowing (JSN) progression and bone marrow lesion (BML) volume change
JSN progression
Rank for change in BML volume Median
(min, max) cm3




Medial or lateral JSN progression (n = 350)
BML regression (n = 87) -0.97 (-12.59, -0.46) 66 (76%) 21 (24%) 1.86 (0.96 to 3.60)
No to minimal BML change (n = 176)
(middle two quartiles collapsed)
-0.05 (-0.46, 0.24) 150 (85%) 26 (15%) Reference 0.11
BML progression (n = 87) 0.73 (0.25, 10.02) 66 (76%) 21 (24%) 1.79 (0.92 to 3.46)
Medial JSN progression (n = 301)
Medial TF BML regression (n = 75) -0.97 (-9.48, -0.46) 53 (74%) 19 (26%) 3.07 (1.44 to 6.57)
No to minimal medial TF BML change (n = 151)
(middle two quartiles collapsed)
-0.08 (-0.46, 0.23) 130 (89%) 16 (11%) Reference 0.01
Medial TF BML progression (n = 75) 0.65 (0.23, 4.76) 58 (81%) 14 (19%) 1.62 (0.73 to 3.61)
All changes are based on change between the 24- and 48-month Osteoarthritis Initiative visits. *Odds ratios are adjusted for sex, baseline age (<65 years, ≥65
years), and baseline body mass index (<30 kg/m2, ≥30 kg/m2). 95% CI, 95% confidence interval; TF, tibiofemoral.
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of omitting some areas of high signal intensity and mea-
surement error associated with this semi-automated
approach. If the measurement error was random, then
the error would have increased the likelihood of null
results. In addition to measurement error, it is important
to acknowledge that these results may be specific to the
MR sequence we measured. Future research may be war-
ranted to confirm these findings on other MR sequences.
Another limitation to these analyses is that there were
only two time points measured. One study has suggested
that BML change may occur within six to twelve weeks
[15]. Therefore, it is difficult to determine when the BML
volume change occurred within the two-year follow-up
period. If the BML volume change primarily occurred in
the last few months of the follow-up period, then there
may not have been adequate time to observe the benefits
of BML regression. These findings highlight the impor-
tance of future research to measure BML volume change
over multiple time periods, with shorter intervals
between assessments, to evaluate how fluctuations in
BML size relate to disease progression. Studies with mul-
tiple time points may be key to understanding whether
the joint remains compromised once a large BML
emerges. This may be particularly relevant for clinical
trials that aim to reduce BML size [40]; particularly since
these studies may be ideal for determining the clinical
meaningfulness of the association between change in
BML volume and change in pain.
Besides being limited to two time points, this study was
also limited by 68 cases of JSN progression among
375 knees. This limitation may have been greater if BML
changes were classified based on semi-quantitative
changes, which offers a limited range for scoring change.
In this study, BML volume was advantageous because it
provided a continuous outcome that could be stratified
into groups (for example, tertiles, quartiles) and within
these groups have sufficient heterogeneity for regression
models. Notwithstanding this advantage, longer follow-up
periods or larger sample sizes may help increase the num-
ber of knees with JSN progression in future studies.
Finally, we used a convenience sample selected from
the OAI progression subcohort, which may introduce a
selection bias. The OAI progression subcohort included
individuals from four clinical sites (Rhode Island, Mary-
land, Pennsylvania, Ohio) with at least one knee with
symptomatic knee OA. The OAI is not a population-
based sample but is a well-described study sample with a
rich dataset including MR imaging, clinical variables, and
biospecimens. Furthermore, within this subcohort we
analyzed 404 knees, which had a similar age, weight, and
height to the rest of the progression cohort but included
less females, less knees with radiographic OA, and knees
with less WOMAC pain scores (Table 1). This may intro-
duce some bias but, despite this limitation, our analyses
with joint symptoms complement the existing literature
and our structural analyses using the OAI data was con-
sistent with the confirmatory analyses using the clinical
trial data.
Despite these limitations, this study may demonstrate
that once a knee experiences a large BML the joint has
been structurally compromised, at least for 24 months.
Additional research will be needed to test hypotheses for
why this may be the case (for example, despite BML
regression on MR images the bone structure remains
compromised). Based on these hypotheses, prevention of
large BMLs may be a more desirable therapeutic goal
than trying to reduce BML size.
Conclusions
In conclusion, this study provides further evidence that
baseline BML size in an important imaging biomarker
associated with greater baseline knee pain, the presence
of structural damage at baseline, and OA progression.
However, this study did not support the use of BML
volume change as a surrogate endpoint. We found that
BML regression was associated with decreases in knee
pain but not a change in risk for structural progression
over 24 months. Based on secondary analyses (CART
analysis), small baseline BMLs may not be associated
with JSN progression, regardless of BML change, but
among knees with larger baseline BMLs the chance of
JSN progression is influenced by baseline BML size and
change in BML size.
Additional material
Additional file 1: Figure S1. Classification and regression trees intended
to classify participants with and without joint space narrowing
progression. The analysis classified participants with baseline bone
marrow lesion (BML) volume less than 0.95 cm3 as participants without
joint space narrowing (JSN) progression. For participants with baseline
BML volume greater than 0.95 cm3, classification into the progressor and
non-progressor groups depended on further splits based on change in
BML volume, baseline BML volume, and age.
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